NEWTON, Mass.--(BUSINESS WIRE)--May 24, 2006-- Matritech (Amex: MZT - News) reported today that independent clinical investigators recommended the NMP22® BladderChek® Test be included in standard practice for diagnosing and monitoring bladder cancer. The test was featured and included in a number of presentations, which highlighted the clinical utility of the point-of-care urine diagnostic test in bladder cancer diagnosis, monitoring and screening, at this year’s 101st Annual Meeting of the American Urological Association (AUA) in Atlanta.
